keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28723914/safety-and-pharmacodynamics-of-dalazatide-a-kv1-3-channel-inhibitor-in-the-treatment-of-plaque-psoriasis-a-randomized-phase-1b-trial
#1
Eric J Tarcha, Chelsea M Olsen, Peter Probst, David Peckham, Ernesto J Muñoz-Elías, James G Kruger, Shawn P Iadonato
BACKGROUND: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases, including psoriasis. OBJECTIVE: The primary objective was to evaluate the safety of repeat doses of dalazatide in adult patients with mild-to-moderate plaque psoriasis. Secondary objectives were to evaluate clinical proof of concept and the effects of dalazatide on mediators of inflammation in the blood and on chronically activated memory T cell populations...
2017: PloS One
https://www.readbyqxmd.com/read/28716831/coronary-plaque-characterization-in-psoriasis
#2
EDITORIAL
Dario Kivelevitch, Jeffrey M Schussler, Alan Menter
No abstract text is available yet for this article.
July 18, 2017: Circulation
https://www.readbyqxmd.com/read/28714180/tofacitinib-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-in-japanese-patients-subgroup-analyses-from-a-randomized-placebo-controlled-phase-3-trial
#3
Masatoshi Abe, Chikako Nishigori, Hideshi Torii, Hironobu Ihn, Kei Ito, Makoto Nagaoka, Naoki Isogawa, Isao Kawaguchi, Yukiko Tomochika, Mihoko Kobayashi, Anna M Tallman, Kim A Papp
Tofacitinib is an oral Janus kinase inhibitor. These post-hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52-week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo-treated patients advanced to tofacitinib at week 16. Primary efficacy end-points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (PASI-75) and Physician's Global Assessment (PGA) of "clear" or "almost clear" (PGA response) at week 16...
July 17, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28707649/receptor-for-advanced-glycation-end-products-is-overexpressed-in-psoriatic-plaques-independent-of-disease-severity
#4
Ozkay Ozgor, Gulsen Akoglu, Nuran Sungu, Eda Karaismailoglu, Akin Aktas
BACKGROUND: Enhanced expression and excitation of the receptor for advanced glycation end products is considered to play a role in the regulation of many pro-inflammatory genes involved in the pathogenesis of psoriasis. AIM: We investigated the expression of receptor for advanced glycation end product in various cell types, in lesional and peri-lesional skin of patients with psoriasis, and its correlation with disease severity. METHODS: Paraffin-embedded punch biopsy tissue taken from psoriatic plaques and peri-lesional normal appearing skin tissue of twenty patients with psoriasis, and normal skin samples of eleven healthy participants, were enrolled in the study...
July 14, 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28704992/serum-levels-of-tumor-necrosis-factor-alpha-in-patients-with-psoriasis-before-during-and-after-narrow-band-uvb-phototherapy
#5
Maria T Rossi, Marina Venturini, Arianna Zanca, Mariachiara Arisi, Marta Fusano, Alessandra Sottini, Federico Serana, Luisa Imberti, Piergiacomo Calzavara-Pinton
BACKGROUND/PURPOSE: Narrow-band UVB (NB-UVB) phototherapy is widely used worldwide for moderate and severe psoriasis, which is a chronic autoimmune inflammatory disease characterized by skin infiltrates of Th1-, Th17- and Th22-cells releasing locally pro- inflammatory cytokines. We investigate serum levels of tumor necrosis factor-α (TNF-α) in psoriatic patients before and after NB-UVB phototherapy. METHODS: Twenty-eight subjects with moderate/severe plaque type psoriasis were enrolled...
July 11, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28695989/efficacy-and-safety-of-secukinumab-in-treating-moderate-to-severe-plaque-psoriasis-in-two-real-world-canadian-dermatology-clinics-a-multicenter-retrospective-study
#6
J R Georgakopoulos, A Ighani, L L Zhou, J Yeung
Secukinumab is an interleukin (IL)-17A antagonist approved in 2015 by health agencies around the world for the treatment of moderate to severe plaque psoriasis in adult patients. Current knowledge of the efficacy and safety of secukinumab is limited to data from phase III randomized controlled trials (RCT). Despite the acceptable safety profile and promising efficacy results, there remains to be a lack of understanding of treatment outcomes in real-world clinical practice. This article is protected by copyright...
July 11, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28695330/the-metabolic-analysis-of-psoriasis-identifies-the-associated-metabolites-while-providing-computational-models-for-the-monitoring-of-the-disease
#7
Aigar Ottas, Dmytro Fishman, Tiia-Linda Okas, Külli Kingo, Ursel Soomets
The majority of studies on psoriasis have focused on explaining the genetic background and its associations with the immune system's response. The aim of this study was to identify the low-molecular weight compounds contributing to the metabolomic profile of psoriasis and to provide computational models that help with the classification and monitoring of the severity of the disease. We compared the results from targeted and untargeted analyses of patients' serums with plaque psoriasis to controls. The main differences were found in the concentrations of acylcarnitines, phosphatidylcholines, amino acids, urea, phytol, and 1,11-undecanedicarboxylic acid...
July 10, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28691952/intrapatient-variability-in-the-pharmacokinetics-of-etanercept-maintenance-treatment
#8
Ji S van Bezooijen, Marco W J Schreurs, Birgit C P Koch, Henk Te Velthuis, Martijn B A van Doorn, Errol P Prens, Teun van Gelder
AIM: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness. A high intrapatient variability (IPV) of etanercept trough concentrations at standard dosing would reduce the feasibility of therapeutic drug monitoring. Studies have focused on the interpatient differences associated with the exposure to biologics. The aim of this study was to determine IPV of etanercept and correlate etanercept trough concentrations and IPV with treatment response...
August 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28691207/hyperuricemia-is-an-independent-risk-factor-for-psoriatic-arthritis-in-psoriatic-patients
#9
Noriko Tsuruta, Shinichi Imafuku, Yutaka Narisawa
Psoriatic arthritis (PsA) is a spondyloarthritic condition mainly seen in patients with psoriasis. Psoriatic patients with plaques on the scalp, gluteal fold or nail lesions are known to develop PsA more frequently, but other markers for PsA have not yet been identified. To determine which psoriatic patients are at greatest risk of developing PsA, psoriasis vulgaris (PsV) patients who visited the Department of Dermatology, Fukuoka University Hospital in 2015 were enrolled. Patients with and without PsA were statistically compared with respect to age, sex, age at onset, body mass index (BMI), smoking and drinking habits, familial history of psoriasis and comorbidities...
July 10, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28690516/eruptive-seborrheic-keratoses-restricted-to-plaque-patch-stage-mycosis-fungoides
#10
Eve Lebas, Pascale Quatresooz, Jorge E Arrese, Arjen F Nikkels
Eruptive seborrheic keratoses (ESK) are rare in dermatology. They are usually inflammatory in nature and may be encountered as Leser-Trélat sign. ESK may also be simultaneously observed with hepatic angiomas, chemotherapy, segmental neurofibromatosis, HIV or erythrodermic pityriasis rubra pilaris, psoriasis, and drug eruption. ESK may be transient and self-healing. Others recede after successful treatment of the underlying disease. In some instances, seborrheic keratoses may follow an isotopic response and remain strictly restricted to sites of previous eczema, photo-exposition or tattoos...
May 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28686753/narrowband-uvb-treatment-increases-serum-25-hydroxyvitamin-d-levels-in-patients-with-chronic-plaque-psoriasis
#11
Seyamak Saleky, Isil Bulur, Zeynep N Saraçoğlu
The aim of this study was to investigate the effects of narrowband UVB (NB-UVB) phototherapy on serum 25-hydroxyvitamin D (25[OH]D) levels and related parameters in patients with psoriasis. Forty-nine participants with moderate to severe plaque-type psoriasis were included in this study and were treated with NB-UVB therapy 3 times weekly for 6 months or until psoriasis area and severity index (PASI) 75 was achieved. Participants' serum 25(OH)D, calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase (ALP) levels were measured at baseline and completion of treatment, along with PASI scores...
June 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28677075/urticarial-reaction-to-ustekinumab-during-the-treatment-of-plaque-psoriasis-in-a-hepatitis-c-positive-patient
#12
Christopher H Chu, Charles Davis
A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated...
December 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/28673565/monocyte-subpopulations-study-in-patients-with-plaque-psoriasis
#13
Mariana Carvalho Costa, Bruno de Oliveira Rocha, Camilla Sampaio Paixão, Maria de Fátima Santos Paim de Oliveira, Lícia Maria Henrique da Mota, Lucas Pedreira de Carvalho
Psoriasis is a chronic and systemic, immune-mediated, inflammatory disease, mainly manifested by skin and / or joints lesions, presenting with a wide degree of clinical severity, but generally with great impact on patients' quality of life. Despite advances in the understanding of its pathogenesis, especially regarding the participation of T-lymphocytes and the key role of TNF, the triggering factor of the disease at the molecular level remains unknown, as well as the function of other cell populations. By presenting antigens to T-lymphocytes, monocytes assume an important role in both innate and adaptive immune response...
July 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28667200/quality-of-life-treatment-satisfaction-and-efficacy-of-non-biological-systemic-therapies-in-patients-with-plaque-psoriasis-study-protocol-for-a-prospective-observational-study
#14
Christine Fink, Timo E Schank, Nina Trenkler, Lorenz Uhlmann, Knut Schäkel
INTRODUCTION: Psoriasis vulgaris often leads to a significant impaired quality of life and dissatisfaction with the existing therapeutic approaches. However, patients' quality of life and treatment satisfaction are of utmost importance, since it is positively related to therapy adherence and encourages patient's compliance. The study described herein evaluates the quality of life, treatment satisfaction and efficacy during the initial 6 months of treatment with a non-biological systemic agent in a real-life clinical setting...
June 30, 2017: BMJ Open
https://www.readbyqxmd.com/read/28667056/endogenous-endophthalmitis-and-osteomyelitis-associated-with-interleukin-17-inhibitor-treatment-for-psoriasis-in-a-patient-with-diabetes
#15
Christine E Martinez, John B Allen, Frederick H Davidorf, Colleen M Cebulla
A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive Staphylococcus aureus endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4 weeks prior to presentation...
June 29, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28665918/topical-corticosteroids-or-vitamin-d-analogues-for-plaque-psoriasis
#16
Soledad Venegas-Iribarren, Romina Andino
Psoriasis is a frequent chronic inflammatory disease. The plaque variant being its most common form of presentation. Although there is still no cure, treatment alternatives that induce remission and reduce lesions are available. Topical therapies, particularly corticosteroids and vitamin D analogues, are considered effective, but it is still not clear which would be the best alternative. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others...
June 27, 2017: Medwave
https://www.readbyqxmd.com/read/28664285/-psoriasis-vs-psoriatic-arthritis-similarities-and-differences-in-the-pathophysiology
#17
T Pap, C Sunderkötter
Psoriasis is a chronic inflammatory skin disease with genetic and (auto)immunological backgrounds. Up to 30% of patients with psoriasis also develop a mostly oligoarticular arthritis with spinal involvement that is termed psoriatic arthritis (PsA) and shows a specific joint pattern which differs from that of rheumatoid arthritis (RA). Both Psa and psoriasis share a common main axis, the interleukin (IL) 23/IL17 pathway as well as major overlaps in the functions of tumor necrosis factor alpha (TNFalpha)...
June 29, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28659016/calcipotriene-betamethasone-dipropionate-aerosol-foam-in-the-treatment-of-plaque-psoriasis-a-review-of-the-literature
#18
Jillian Frieder, Dario Kivelevitch, Alan Menter
Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i.e., psoriatic arthritis, Crohn's disease and cardiovascular disease). A greater understanding of its immunopathogenesis has guided the development of novel, more targeted therapies. Nonetheless, traditional treatment with topical agents, phototherapy and systemic medications is used in the management of the majority of psoriasis patients. Mainstay topical treatments include corticosteroids and vitamin D derivatives...
June 29, 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28653490/the-role-of-il-23-and-the-il-23-th-17-immune-axis-in-the-pathogenesis-and-treatment-of-psoriasis
#19
REVIEW
G Girolomoni, R Strohal, L Puig, H Bachelez, J Barker, W H Boehncke, J C Prinz
Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The etiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious, and lifestyle factors. The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive. However, the interleukin 23 (IL-23)/T-helper 17 (TH 17) immune axis has been identified as a major immune pathway in psoriasis disease pathogenesis...
June 27, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28652702/spotlight-on-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-design-development-and-use-in-therapy
#20
REVIEW
Alessandro Giunta, Alessandra Ventura, Maria Sole Chimenti, Luca Bianchi, Maria Esposito
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population, associated with discomfort and impaired quality of life. In recent years, the pathogenic cytokine network of psoriasis has been extensively studied leading to the development of new treatments that provide greater efficacy. Interleukin 17A (IL-17A) has been recognized as a crucial cytokine that mediates immunopathogenesis of psoriasis. Ixekizumab - indicated for the treatment of adults with moderate-to-severe plaque psoriasis - is a subcutaneously administered humanized monoclonal antibody that targets IL-17A...
2017: Drug Design, Development and Therapy
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"